Phase II study of cytarabine in Hodgkin's disease

José Thomas, Ben de Pauw, Anton Hagenbeek, Reinier Somers, Patrice Carde, Umberto Tirelli, Nicole Duez

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Cytarabine was administered to 24 patients with previously treated Hodgkin's disease in the EORTC Lymphoma Cooperative Group. The drug was administered at the dose of 80 mg/m2 subcutaneously twice a day on 5 consecutive days every 3 weeks. The overall response rate was 17.6% (3 responses among 17 evaluable patients) with a short duration (2-6 months). The main toxicity was myelosuppression. Our experience in the EORTC Lymphoma Cooperative Group could not demonstrate a significant activity at this dose and schedule in Hodgkin's disease.

Original languageEnglish
Pages (from-to)857-859
Number of pages3
JournalEuropean Journal of Cancer
Volume28
Issue number4-5
DOIs
Publication statusPublished - 1992

Fingerprint

Cytarabine
Hodgkin Disease
Lymphoma
Appointments and Schedules
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Thomas, J., de Pauw, B., Hagenbeek, A., Somers, R., Carde, P., Tirelli, U., & Duez, N. (1992). Phase II study of cytarabine in Hodgkin's disease. European Journal of Cancer, 28(4-5), 857-859. https://doi.org/10.1016/0959-8049(92)90133-M

Phase II study of cytarabine in Hodgkin's disease. / Thomas, José; de Pauw, Ben; Hagenbeek, Anton; Somers, Reinier; Carde, Patrice; Tirelli, Umberto; Duez, Nicole.

In: European Journal of Cancer, Vol. 28, No. 4-5, 1992, p. 857-859.

Research output: Contribution to journalArticle

Thomas, J, de Pauw, B, Hagenbeek, A, Somers, R, Carde, P, Tirelli, U & Duez, N 1992, 'Phase II study of cytarabine in Hodgkin's disease', European Journal of Cancer, vol. 28, no. 4-5, pp. 857-859. https://doi.org/10.1016/0959-8049(92)90133-M
Thomas J, de Pauw B, Hagenbeek A, Somers R, Carde P, Tirelli U et al. Phase II study of cytarabine in Hodgkin's disease. European Journal of Cancer. 1992;28(4-5):857-859. https://doi.org/10.1016/0959-8049(92)90133-M
Thomas, José ; de Pauw, Ben ; Hagenbeek, Anton ; Somers, Reinier ; Carde, Patrice ; Tirelli, Umberto ; Duez, Nicole. / Phase II study of cytarabine in Hodgkin's disease. In: European Journal of Cancer. 1992 ; Vol. 28, No. 4-5. pp. 857-859.
@article{c80ab767d0084b05a4718f56a6c48ebf,
title = "Phase II study of cytarabine in Hodgkin's disease",
abstract = "Cytarabine was administered to 24 patients with previously treated Hodgkin's disease in the EORTC Lymphoma Cooperative Group. The drug was administered at the dose of 80 mg/m2 subcutaneously twice a day on 5 consecutive days every 3 weeks. The overall response rate was 17.6{\%} (3 responses among 17 evaluable patients) with a short duration (2-6 months). The main toxicity was myelosuppression. Our experience in the EORTC Lymphoma Cooperative Group could not demonstrate a significant activity at this dose and schedule in Hodgkin's disease.",
author = "Jos{\'e} Thomas and {de Pauw}, Ben and Anton Hagenbeek and Reinier Somers and Patrice Carde and Umberto Tirelli and Nicole Duez",
year = "1992",
doi = "10.1016/0959-8049(92)90133-M",
language = "English",
volume = "28",
pages = "857--859",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "4-5",

}

TY - JOUR

T1 - Phase II study of cytarabine in Hodgkin's disease

AU - Thomas, José

AU - de Pauw, Ben

AU - Hagenbeek, Anton

AU - Somers, Reinier

AU - Carde, Patrice

AU - Tirelli, Umberto

AU - Duez, Nicole

PY - 1992

Y1 - 1992

N2 - Cytarabine was administered to 24 patients with previously treated Hodgkin's disease in the EORTC Lymphoma Cooperative Group. The drug was administered at the dose of 80 mg/m2 subcutaneously twice a day on 5 consecutive days every 3 weeks. The overall response rate was 17.6% (3 responses among 17 evaluable patients) with a short duration (2-6 months). The main toxicity was myelosuppression. Our experience in the EORTC Lymphoma Cooperative Group could not demonstrate a significant activity at this dose and schedule in Hodgkin's disease.

AB - Cytarabine was administered to 24 patients with previously treated Hodgkin's disease in the EORTC Lymphoma Cooperative Group. The drug was administered at the dose of 80 mg/m2 subcutaneously twice a day on 5 consecutive days every 3 weeks. The overall response rate was 17.6% (3 responses among 17 evaluable patients) with a short duration (2-6 months). The main toxicity was myelosuppression. Our experience in the EORTC Lymphoma Cooperative Group could not demonstrate a significant activity at this dose and schedule in Hodgkin's disease.

UR - http://www.scopus.com/inward/record.url?scp=0026605351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026605351&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(92)90133-M

DO - 10.1016/0959-8049(92)90133-M

M3 - Article

C2 - 1524908

AN - SCOPUS:0026605351

VL - 28

SP - 857

EP - 859

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 4-5

ER -